Tonix Pharmaceuticals Holding Corp. has received approval from Nasdaq to transfer the listing of its common stock from the Nasdaq Capital Market to the Nasdaq Global Select Market. Trading on the higher tier is expected to begin at the open of market on March 3, 2026, under the existing ticker symbol "TNXP." The move reflects the company's compliance with the Nasdaq Global Select Market's more stringent financial and corporate governance requirements and is expected to enhance institutional visibility, liquidity and broader market recognition. Management described the uplisting as an important milestone as the company continues to focus on growth and shareholder value creation.
Tonix Pharmaceuticals is a fully-integrated, commercial-stage biotechnology company focused on central nervous system and immunology treatments in areas of high unmet medical need. TONMYA, the company's recently approved flagship medicine, is the first new treatment for fibromyalgia in more than 15 years. Tonix's CNS commercial infrastructure supports its marketed products, including its acute migraine products, Zembrace SymTouch and Tosymra. The company is maximizing the science behind TONMYA in Phase 2 clinical trials to evaluate its potential in major depressive disorder and acute stress disorder.
In addition, the company's CNS portfolio includes TNX-2900, which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare disease. Tonix is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection. The company's product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication.
The latest news and updates relating to TNXP are available in the company's newsroom at https://ibn.fm/TNXP. The full press release can be viewed at https://ibn.fm/uDmmW. The announcement is significant for investors and the biotechnology sector as it signals Tonix's progression toward meeting higher financial and governance standards typically associated with more established public companies. This transition could potentially attract a broader base of institutional investors who are restricted to investing in stocks listed on higher-tier exchanges, thereby increasing trading volume and potentially stabilizing the stock's price.
For the pharmaceutical industry, Tonix's uplisting represents validation of its commercial-stage status and diversified pipeline targeting central nervous system disorders and immunology. The company's focus on areas with high unmet medical need, including fibromyalgia, Prader-Willi syndrome, and transplant rejection, highlights the ongoing demand for innovative treatments in challenging therapeutic areas. As Tonix prepares to begin trading on the Nasdaq Global Select Market in 2026, the move may serve as a benchmark for other emerging biotechnology companies seeking to advance from development-stage to commercial-stage status while meeting increasingly rigorous market requirements.
